Persistence of antibodies and immune memory to hepatitis B vaccine 20 years after infant vaccination in Thailand

Vaccine

Volumn 28, Issue 3, 2010, Pages 730-736

  Poovorawan, Yong ^a   Chongsrisawat, Voranush ^a   Theamboonlers, Apiradee ^a   Bock, Hans L ^b   Leyssen, Maarten ^b   Jacquet, Jeanne Marie ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Booster; Hepatitis B; Vaccine

Indexed keywords

HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG FATALITY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; SEROPREVALENCE; THAILAND; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VACCINATION;

ANTIBODIES, VIRAL; FEMALE; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOLOGIC MEMORY; INFANT; LONGITUDINAL STUDIES; MALE; THAILAND; VACCINATION;

EID: 71149083714     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.074     Document Type: Article

References (23)

1. World Health Organization. Hepatitis B vaccines WHO position paper. WER 2004; 79:255-63.
2. Goldstein S.T., Zhou F., Hadler S.C., Bell B.P., Mast E.E., and Margolis H.S. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol 34 6 (2005) 1329-1339
3. Zanetti A.R., Van Damme P., and Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26 49 (2008) 6266-6273
4. Chongsrisawat V., Yoocharoen P., Theamboonlers A., Tharmaphornpilas P., Warinsathien P., Sinlaparatsamee S., et al. Hepatitis B seroprevalence in Thailand: 12 years after hepatitis B vaccine integration into the national expanded programme on immunization. Trop Med Int Health 11 10 (2006) 1496-1502
5. Chien Y.C., Jan C.F., Kuo H.S., and Chen C.J. Nationwide hepatitis B vaccination program in Taiwan: effectiveness in the 20 years after it was launched. Epidemiol Rev 28 (2006) 126-135
6. Ng K.P., Saw T.L., Baki A., Rozainah K., Pang K.W., and Ramanathan M. Impact of the expanded program of immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol (Berl) 194 3 (2005) 163-168
7. European Consensus Group on Hepatitis B Immunity. Are booster immunisations needed for lifelong hepatitis B immunity?. Lancet 355 (2000) 561-565
8. Van Damme P., and Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 5 (2007) 79-84
9. Lu C.Y., Ni Y.H., Chiang B.L., Chen P.J., Chang M.H., Chang L.Y., et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 197 10 (2008) 1419-1426
10. Su F.H., Cheng S.H., Li C.Y., Chen J.D., Hsiao C.Y., Chien C.C., et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 25 47 (2007) 8085-8090
11. Wang L.Y., and Lin H.H. Short-term response to a booster dose of hepatitis B vaccine in anti-HBs negative adolescents who had received primary vaccination 16 years ago. Vaccine 25 (2007) 7160-7167
12. Bialek S.R., Bower W.A., Novak R., Helgenberger L., Auerbach S.B., Williams I.T., et al. Persistence of protection against hepatitis B virus infection among adolescents vaccinated with recombinant hepatitis B vaccine beginning at birth: a 15-year follow-up study. Pediatr Infect Dis J 27 10 (2008) 881-885
13. Hammitt L.L., Hennessy T.W., Fiore A.E., Zanis C., Hummel K.B., Dunaway E., et al. Hepatitis B immunity in children vaccinated with recombinant hepatitis B vaccine beginning at birth: a follow-up study at 15 years. Vaccine 25 39-40 (2007) 6958-6964
14. Keating G.M., and Noble S. Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 63 10 (2003) 1021-1051
15. Poovorawan Y., Sanpavat S., Pongpunlert W., Chumdermpadetsuk S., Sentrakul P., Chitinand S., et al. Comparison of a recombinant DNA hepatitis B vaccine alone or in combination with hepatitis B immune globulin for the prevention of perinatal acquisition of hepatitis B carriage. Vaccine 8 Suppl. (1990) S56-S59
16. Poovorawan Y., Sanpavat S., Pongpunglert W., Chumdermpadetsuk S., Sentrakul P., Vandepapelière P., et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr Infect Dis J 11 10 (1992) 816-821
17. Poovorawan Y., Sanpavat S., Chumdermpadetsuk S., and Safary A. Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch Dis Child Fetal Neonatal Ed 77 1 (1997) F47-F51
18. Poovorawan Y., Chongsrisawat V., Theamboonlers A., Hutagalung Y., Jacquet J.M., and Leyssen M. 20-year persistence of immune response to infant hepatitis B vaccination in a high endemicity region. Program and Abstracts of the 13th International Symposium on Viral Hepatitis and Liver Disease. Washington, DC (2009)
19. Dawson B., and Trapp R.G. Research questions about two separate or independent groups. In: Dawson B., and Trapp R.G. (Eds). Basic & Clinical Biostatistic. 4th ed. (2004), McGraw-Hill, New York 134-161
20. Samandari T., Fiore A.E., Negus S., Williams J.L., Kuhnert W., McMahon B.J., et al. Differences in response to a hepatitis B vaccine booster dose among Alaskan children and adolescents vaccinated during infancy. Pediatrics 120 2 (2007) e373-e381
21. But D.Y., Lai C.L., Lim W.L., Fung J., Wong D.K., and Yuen M.F. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 26 51 (2008) 6587-6591
22. Alfaleh F., Alshehri S., Alansari S., Aljeffri M., Almazrou Y., Shaffi A., et al. Long-term protection of hepatitis B vaccine in Saudi Arabia 18 years after vaccination. J Infect 57 5 (2008) 404-409
23. Chinchai T., Chirathaworn C., Praianantathavorn K., Theamboonlers A., Hutagalung Y., Bock P.H., et al. Long-term humoral and cellular immune response to hepatitis B vaccine in high-risk children 18-20 years after neonatal immunization. Viral Immunol 22 2 (2009) 125-130